TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

ONYX PHARMS AMGEN

OncologyImmunologyMetabolic
Specialty

ONYX PHARMS AMGEN is a specialty pharmaceutical company focused on Oncology, Immunology, Metabolic. Key products include KYPROLIS.

2012
Since
1
Drugs
-
Trials
1
Approved (2yr)

Key Drugs

KYPROLIS
carfilzomib
Oncology
20S proteasome 1 indications · 2012

Recent Activity

KYPROLIS 2025-05-22
Efficacy
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 42%
1 drugs Phase 3: 25 Phase 2: 15 Phase 1: 70
Immunology 23%
0 drugs Phase 3: 19 Phase 2: 13 Phase 1: 13
Metabolic 18%
0 drugs Phase 3: 15 Phase 2: 4 Phase 1: 20
Cardiovascular 9%
0 drugs Phase 3: 9 Phase 2: 1 Phase 1: 4
Dermatology 8%
0 drugs Phase 3: 8 Phase 2: 3 Phase 1: 3

Pipeline Strength Pro

Loading...

Competitors Pro

Merck big-pharma
Oncology, Cardiovascular, Immunology, Metabolic
Johnson & Johnson big-pharma
Oncology, Immunology, Cardiovascular, Metabolic
Eli Lilly big-pharma
Metabolic, Oncology, Immunology, Dermatology
Bayer big-pharma
Oncology, Cardiovascular, Dermatology, Metabolic
AstraZeneca big-pharma
Oncology, Cardiovascular, Metabolic, Immunology